This trial is active, not recruiting.

Condition pulmonary idiopathic arterial hypertension
Sponsor Unidad de Investigacion Clinica en Medicina S.C.
Start date August 2007
End date February 2008
Trial size 25 participants
Trial identifier NCT00551408, 07-012, UDICEM07-012


Endothelial dysfunction ultimately represents an imbalance between the magnitude of injury and the capacity for repair.

Current evidence established that endothelial progenitor cells (EPC) participate in several models of vascular disease as acute coronary syndromes, stroke, diabetes, peripheral artery disease, etc. However EPC in the setting of PAH is less well established. The target of this study is to demonstrate if the number of EPC is increased in a mexican population of patients with PAH.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective

Eligibility Criteria

Male or female participants from 18 years up to 70 years old.

Inclusion Criteria: - Patients were included in the study if they were in The WHO functional class II to III, and had a mean pulmonary artery pressure >30 mm Hg on right heart catheterization. The ability to walk >50 m during a standardized 6-min walk test. Exclusion Criteria: - Pulmonary hypertension as a result of heart disease, pulmonary disease, sleep-associated disorders, chronic thromboembolic disease, autoimmune or collagen vascular disease, HIV infection, liver disease, major bleeding requiring blood transfusion,renal dysfunction, and evidence for malignant diseases were excluded.

Additional Information

Official title The Determination of Endothelial Progenitor Cells in Pulmonary Idiopathic Arterial Hypertension.
Principal investigator Carlos J Sanchez Diaz, MD.
Trial information was received from ClinicalTrials.gov and was last updated in October 2007.
Information provided to ClinicalTrials.gov by Unidad de Investigacion Clinica en Medicina S.C..